The goal of medical research is to produce the knowledge, treatments, and medicines that help people in need. As the National Institutes of Health and the National Cancer Institute funded medical research continues to produce scientific breakthroughs, the Food and Drug Administration (FDA) serves as the nexus between new discoveries and routine cancer care. All new cancer treatments must be reviewed and approved by the FDA before being available to cancer patients.

The FDA plays dual roles in its mission to protect and promote public health. While public safety is paramount when evaluating, approving and monitoring new products, the FDA must balance this with the role of providing patients access to potentially life-saving medicines. A chronic lack of resources at the FDA has resulted in insufficient IT systems, challenges with personnel recruitment, training and retention, and the inability to develop advanced methods and tools for product evaluation. Providing the FDA the resources that it requires to further integrate cutting-edge science will help breakthroughs move more rapidly into clinical practice while protecting patients from treatments that do not work or are unsafe.

By some estimates, there are over 800 new, potentially life saving, cancer therapies currently in development. New oncology applications are the most active area of FDA medical product regulation. With appropriate resources, the FDA will be able to develop a seamless, cross-disciplinary, cross-center approach to product review, so that the best possible expertise is brought to bear on any specific problem, and to ensure consistency.

Increases in the FDA’s budget would:
- Allow the FDA to provide faster and safer approval of products that are saving lives and transforming health care;
- Promote new drug technologies that will revolutionize pharmaceutical therapies;
- Ensure continued U.S. leadership in drug innovation;
- Enhance the surveillance capability over new drugs once they reach the market; and,
- Further integrate emerging science into the regulatory process.

For millions of patients, a stalled pipeline means a delay of life-saving products. All patients benefit when the FDA has more resources.

**OVAC urges Congress to provide the FDA with at least $2.857 billion in FY11.**